
CRBP Stock Forecast & Price Target
CRBP Analyst Ratings
Bulls say
Corbus Pharmaceuticals Holdings Inc. is positioned favorably in the precision oncology sector, driven by promising developments in its pipeline, particularly CRB-701 and CRB-601. The recent presentation of updated data at ASCO GU 2025 indicates a compelling 44% overall response rate for CRB-701, highlighting its potential in both efficacy and safety compared to existing ADCs like Tivdak, without significant dose-limiting toxicities. Additionally, the ongoing development of CRB-601, which targets αvβ8 integrins to inhibit the activation of latent TGFβ, enhances the company's portfolio appeal, suggesting robust growth prospects as these therapies advance through clinical evaluation.
Bears say
Corbus Pharmaceuticals Holdings Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily driven by the risk of regulatory approval delays and clinical trial failures related to its drug candidates, including CRB-913 and CRB-601. These factors, combined with concerns over the competitive landscape influenced by Novo Nordisk's new obesity treatments, suggest that the current valuation may be overly optimistic and not justified by the company's pipeline. Furthermore, complications such as ocular toxicity associated with Tivdak may hinder market adoption and impede revenue generation, further exacerbating the company's financial uncertainties.
This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.
CRBP Analyst Forecast & Price Prediction
Start investing in CRBP
Order type
Buy in
Order amount
Est. shares
0 shares